Sequana Medical NV, a commercial stage medical device company, engages in the development of platform for the treatment of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; Direct Sodium Removal (DSR) for the treatment of persistent congestion due to heart failure; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with fluid overload due to heart failure. It operates in Belgium, Germany, France, Switzerland, and internationally. The company was founded in 2006 and is headquartered in Ghent, Belgium.

Sequana Medical NV

SAFRA Group is involved in automobile services, including bodywork, mechanical support, and furniture manufacturing. The group emphasizes a comprehensive approach to environmental, economic, and social responsibility.

SAFRA Group

SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. It offers orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. The company's orthobiologics products include demineralized bone matrix (DBM), collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to improve bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. It also offers orthobiologics products in various forms, such as fibers, putties, pastes, strips, and DBM. In addition, the company offers implant products for spinal decompression, alignment, stabilization, and image-guided surgical solutions, as well as a surgical navigation system used to facilitate fusion in degenerative, minimally invasive, and complex spinal deformity procedures throughout the lumbar, thoracic, and cervical regions of the spine. SeaSpine Holdings Corporation was incorporated in 2015 and is headquartered in Carlsbad, California.

Metric
Company Name	Sequana Medical NV	SAFRA Group	SeaSpine Holdings Corporation
Symbol	SEQUA		SPNE
MSH ID	COM:SEQUANAMEDICAL	COM:GROUPESAFRA	COM:SEASPINE
Market	STOCKS	PRIVATE	STOCKS
Sector	Healthcare	Consumer Services	Healthcare
Industry	Medical - Devices	Automotive Services	Medical - Devices
Country	BE	FR	US
Stage
Employee Count	62		523
Website	sequanamedical.com	groupesafra.com	seaspine.com
LinkedIn
Founders

Metric
Market Cap	42.61M
Enterprise Value
Monthly Web Traffic		28.98K	1.86K
Web Traffic Growth		-0.43	-0.23
Valuation
Raised Capital

Metric
Revenue	752.04K	191.45M
Revenue (LTM)
Revenue (NTM)
Gross Profit	-4.39M	114.59M
EBITDA	-30.45M	-55.45M
Operating Income	-31.15M	-60.98M
Net Income	-34.40M	-54.35M
EPS	-1.29	-1.62
Diluted EPS	-1.29	-1.62
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.77	0.60
Operating Profit Margin	-36.21	-0.32
EBITDA Margin	-40.49	-0.29
Net Profit Margin	-38.43	-0.28
Return on Equity	16.85	-0.22
Return on Assets	-1.93	-0.14
Return on Capital Employed	4.68	-0.19

COM:SEQUANAMEDICAL

Sequana Medical NV

Last Close

0.85

25/11 08:49

Market Cap

40.33M

Beta: -

Volume Today

3.44K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-2.94	-7.67
P/B Ratio	-41.98	1.29
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	103.14
EV Multiple	-0.21	-1.35

Metric
Days Sales Outstanding		81.67
Days Payables Outstanding	5.76K	98.11
Days Inventory Outstanding	7.30K	343.32
Operating Cycle	7.58K	412.40
Cash Conversion Cycle	1.05K	315.99
Asset Turnover	0.11	0.51

Metric
Operating Cash Flow	-31.68M	-33.51M
Free Cash Flow	-32.43M	-59.55M
Cash Flow to Debt	-1.15	-4.14
Operating Cash Flow/Sales	-36.33	-0.18
Free Cash Flow Yield	-0.25

Metric
Cash & Equivalents	2.73M	83.11M
Accounts Receivable	-573.53K	-7.93M
Inventory	2.43M	72.30M
Goodwill		84.59M
Debt to Capitalization	9.85	0.03
Debt to Assets	0.68	0.12
Current Ratio	1.52	3.18
Quick Ratio	1.28	2.25

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.61	0.06
R&D to Revenue		0.10
SG&A to Revenue	7.25	0.22